Sorbent Dialysate Regeneration Patents: Leaders & White Space 2026
- Three assignees account for all 23 records in scope, with no long tail of smaller filers left outstanding once the ranked leaders are counted.
- Filing activity peaked at 14 records in 2021 and fell to 1 by 2024, a -93% drop across that three-year span that predates the usual 18-month publication lag.
- The two most-cited records in the set are manifold patents for wearable artificial kidneys, cited far ahead of any toxin-removal-loop filing that has followed them.
Filing growth compares 2021 (14 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What sorbent dialysate regeneration covers
Sorbent dialysate regeneration replaces continuous fresh-dialysate supply with a cartridge system that strips urea, ammonia and other toxins from spent dialysate so a small volume of fluid can be recirculated. The approach underpins wearable and portable artificial kidney designs, where cartridge capacity, urease layer chemistry and zirconium phosphate sorbent stages determine how long a device can run before ammonia breakthrough forces a cartridge change. Claims in this space cluster around the fluid manifold that routes dialysate through sorbent stages, the sorbent chemistry itself, and the electrolyte rebalancing needed to correct what the sorbent bed strips out along with the toxins.
The dataset in scope covers 23 published records filed between 2015 and 2026, concentrated overwhelmingly in devices-for-body-fluids classifications with a substantial secondary presence in catalysis and separation-process filings.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 23 records: how filing activity has moved year over year, and which IPC subclasses the claims sit in.
A sharp peak, then a pullback
Filings were essentially flat through 2017, built to a peak of 14 records in 2021, then fell to 1 by 2024 — a -93% move across that three-year span. Because publication lags filing by roughly 18 months, 2025 and 2026 records are still arriving and should not yet be read as a continued decline.
Concentrated in body-fluid devices, with catalysis a strong second
Every record in scope carries an A61M (devices for body fluids) classification. B01J (chemical and physical processes, catalysis) appears in 13 of the 23 records, or 56.5%, reflecting how much of the inventive work sits in sorbent chemistry rather than the fluid circuit alone. B01D (separation processes, including filtration) appears in 7 records, 30.4%, pointing to a smaller but active seam around membrane and filtration stages.
Shares are the percentage of the 23 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Sorbent Dialysate Regeneration with Eureka
This page is one run against one query. Ask Eureka your own question about sorbent dialysate regeneration and every answer comes back with the patent numbers behind it.
Try EurekaThe records shaping this field
Dialysis system incorporating a toxin-removal loop (US20240238493A1, University of Washington, 2024)
A protected fluid circuit uses osmotic or otherwise urea-selective membranes to move urea from spent dialysate to a separate removal side without direct contact, in a forward-osmosis geometry. Paired with an oxidation unit, the design aims for high selective urea flux while balancing patient fluid levels through controlled water evaporation across a vapor-permeable membrane, and protecting the patient-side dialysate/blood loop from oxidation by-products.Abstract text drawn directly from the published filing.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20150314056A1 | Manifold For Wearable Artificial Kidney | 19 |
| 2 | WO2014099631A1 | Manifold for wearable artificial kidney | 11 |
| 3 | WO2022216604A1 | Dialysis system incorporating a toxin-removal loop | 2 |
| 4 | US20240238493A1 | Dialysis system incorporating a toxin-removal loop | 1 |
| 5 | WO2021211060A1 | Dialysate regenerator comprising reversible retainer | 1 |
Citation counts reward older filings that have had more time to accumulate references — read them as a signal of influence on the field's history, not of what matters most today.
Publication numbers are shown where the record carries one (5 of 5 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three findings that shape where a new filing would land relative to existing claims.
No long tail left to map
The top 3 and top 5 figures are identical because only three assignees appear in the ranking at all, and together they account for every record in scope. There is no fragmented periphery of single-filing entrants to watch here — the field is small and already claimed by a short list of organisations.
A sharp pullback after a 2021 peak
Filing activity built steadily to a peak of 14 records in 2021, then dropped to 1 by 2024. That decline sits well before the 18-month publication lag would distort the picture, so it reflects a real reduction in disclosed activity rather than an artefact of recent filings still working through the pipeline.
Influence sits with the manifold, not the sorbent chemistry
The two most-cited records in the dataset both describe manifolds for wearable artificial kidneys rather than sorbent cartridge chemistry itself. Newer toxin-removal-loop filings have accumulated only a fraction of that citation count so far, which is consistent with their more recent publication dates rather than lower relevance.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to sorbent dialysate regeneration, with the prior art for and against each one.
Who holds the claims
Three assignees make up the entire ranked field. None shows filing activity in the latest tracked year, consistent with the broader pullback since the 2021 peak.
One organisation holds close to two-thirds of the set
The leading assignee's 14 records against a field of 23 total gives it a commanding share of everything in scope, well ahead of the other two ranked organisations combined.
University research drives a meaningful share of filings
Two of the three ranked assignees are academic institutions rather than device manufacturers, reflecting how much of the sorbent-regeneration work, particularly on membrane geometry and toxin-removal loops, is still originating in research settings rather than product lines.
A single commercial player anchors the field
Only one of the three ranked assignees is a commercial dialysis-equipment or services company, meaning most of the claim space in this dataset is held by parties whose incentive is publication and licensing rather than direct product defence.
| Assignee | Recent year | YoY |
|---|---|---|
| Temasek Polytechnic | 0 | — |
| University of Washington | 0 | — |
| Fresenius Medical Care Holdings, Inc. | 0 | — |
Where to take this analysis
The dataset points to a small, concentrated field with a clear citation leader and a recent pullback in disclosed activity — but concentration in three assignees does not mean every sub-area is covered.
Check the under-claimed sub-areas before drafting
Ammonia-breakthrough sensing, cartridge-capacity forecasting and electrolyte-rebalancing dosing control do not appear as dedicated claim focuses in this set, which makes them worth a freedom-to-operate check before assuming they are occupied.
Explore white space in EurekaTrack whether the 2021 peak repeats as later years fill in
2025 and 2026 records are still arriving under the normal publication lag, so the apparent decline after 2021 needs revisiting once those years are more complete.
Set up filing alerts in EurekaCommon questions on sorbent dialysate regeneration patents
The ranked field consists of only three assignees, and together they account for all 23 records currently in scope. The leading assignee holds 14 of those records, well ahead of the other two. Two of the three ranked organisations are academic institutions rather than commercial device makers, which is unusual for a field this close to product deployment and suggests licensing rather than direct manufacturing is the likely commercial path for much of the underlying work.
Filing activity peaked at 14 records in 2021 and had fallen to 1 record by 2024, a -93% move across that span. That decline happened well before the point where the usual 18-month publication lag would explain it, so it reflects a genuine slowdown in disclosed filing rather than an artefact of recent applications still working through the publication pipeline. Whether that pattern continues depends on how 2025 and 2026, which are still filling in, ultimately look.
The filing describes a protected fluid circuit that uses osmotic, urea-selective membranes to move urea out of spent dialysate in a forward-osmosis geometry, paired with an oxidation unit for toxin removal. It also covers controlling patient fluid balance through evaporation across a vapor-permeable membrane and protecting the patient-side loop from oxidation by-products. Anyone building a toxin-removal loop with a comparable membrane geometry or oxidation-protection scheme should review this filing's claim scope closely before finalising a design.
Citation weight in this dataset sits with the fluid manifold, not the sorbent chemistry: the two most-cited records both describe manifolds for wearable artificial kidneys. That said, IPC composition shows B01J (catalysis and chemical processes) appearing in 56.5% of the 23 records, so sorbent chemistry claims are far from absent — they are simply newer and have not yet accumulated comparable citation counts.
Several practically important sub-areas — ammonia-breakthrough sensing, cartridge-capacity forecasting, electrolyte-rebalancing dosing control, cost-per-session optimisation and urease-layer degradation monitoring — do not show up as a dedicated claim focus across the 23 records reviewed. That does not guarantee freedom to operate, since claims in adjacent categories may still read on these areas, but it does mark them as worth a targeted search before committing to a filing strategy there.
Research Sorbent Dialysate Regeneration in depth with Eureka
Go past this page: query the whole sorbent dialysate regeneration corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.